Pharvaris (NASDAQ:PHVS) Trading Up 5.3% – Still a Buy?

Pharvaris (NASDAQ:PHVS) shares rose 5.3% during trading on Tuesday . The stock traded as high as $19.84 and last traded at $19.34. Approximately 6,321 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 46,693 shares. The stock had previously closed at $18.36.

Pharvaris Stock Performance

The company’s 50-day moving average price is $19.42 and its 200 day moving average price is $19.33. The stock has a market cap of $1.01 billion, a PE ratio of -6.91 and a beta of -3.06.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio purchased a new position in shares of Pharvaris in the 3rd quarter worth $57,000. Barclays PLC purchased a new position in Pharvaris during the third quarter worth $106,000. Geode Capital Management LLC increased its position in Pharvaris by 18.4% during the third quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock valued at $685,000 after acquiring an additional 5,753 shares during the last quarter. HighVista Strategies LLC raised its stake in shares of Pharvaris by 35.9% in the third quarter. HighVista Strategies LLC now owns 22,768 shares of the company’s stock valued at $422,000 after acquiring an additional 6,018 shares during the period. Finally, Jane Street Group LLC purchased a new position in shares of Pharvaris during the 3rd quarter worth about $526,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.